Skip to content

This medical animation, developed in partnership with Sanofi, showcases their innovation in the field of immunology. The animation presents an efficient and unique treatment for immune dysfunction that targets specific pathways, rather than systemically suppressing the immune system.

An artistic representation showcases proteins interacting with three types of cell receptors—FCR, TLR, and BCR—on a cell membrane. Colorful proteins bind to each receptor, highlighting BTK pathways and immune system processes pivotal in immune mediated diseases.

Sanofi Genzyme oral and topical BTK inhibitors are remarkable in their ability to target Bruton Tyrosine Kinase (BTK), which is found in specific pathways in both innate and adaptive immune cells.

This method stands apart from current treatments that suppress and deplete the immune cells extensively, which can cause increased risk of infection.

A close-up illustration of colorful cells, likely cancer or immune cells, with blue molecules interacting with them. The text reads: BTK inhibitors as targeted therapies for MOD and immune-mediated diseases. The background features a blurred warm gradient.
A colorful 3D rendering of proteins and molecules interacting, with orange, green, and blue structures floating against a blurred purple background. A pink glow highlights a central protein interaction, potentially illustrating BTKs role in immune mediated diseases.

Our scientific animation showcases how Sanofi’s treatment method can mitigate immune system dysregulation by selectively inhibiting BTK across large-scale areas of the body including dermatology, hematology, rheumatology, and neurology.

Related Animations

SOMATIC CELL GENOME EDITING (SCGE)

SOMATIC CELL GENOME EDITING (SCGE)

View